Drug Trial Radar · NCT05815862
Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Aug 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Feb 15, 2023
Primary completion
Aug 20, 2025
Study completion Aug 20, 2025
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-cohort, randomized, open, multicenter Phase II study to evaluate the efficacy and safety of AL2846 capsules in patients with advanced lung cancer and ovarian cancer. Objective response rate (ORR) and progression-free survival (PFS) are the primary endpoints.
Conditions
- Advanced Lung Cancer
- Ovarian Cancer
Interventions
AL2846 capsuleDrug
AL2846 is a multi-target tyrosine kinase inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective remission rate (ORR)Time frame: From baseline up to 12 months.
- Progression free survival (PFS)Time frame: From baseline up to 12 months.
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Shanghai Pulmonary Hospital
Shanghai, China
Hunan Cancer Hospital
Changsha, Hunan, China
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.